Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Appointed director
Beam Therapeutics Inc. (BEAM) Create: Alert

All | News | Filings
Date FiledTypeDescription
11/07/2022 8-K Quarterly results
Docs: "Beam Therapeutics Announces Portfolio Progress and Reports Third Quarter 2022 Financial Results Patient Recruitment Underway in BEACON Clinical Trial of BEAM-101 for Treatment of Sickle Cell Disease as Part of Wave 1strategy Execution IND-enabling Studies Underway for BEAM-301 for Treatment of GSDIa BEAM-302 Nominated as Development Candidate for Treatment of Alpha-1 Antitrypsin Deficiency; Targeting Durable Gene Correction Designed to Address Both Lung and Liver Disease New Data Highlighting Enhanced Conditioning Approach for Hematologic Transplant to be Presented at ASH Ended Third Quarter 2022 with $1.1 Billion in Cash, Cash Equivalents and Marketable Securities CAMBRIDGE, Mass., November 7, 2022 – Beam Therapeutics Inc. , a biotechnology company developing precision genetic medicines t..."
08/09/2022 8-K Quarterly results
05/09/2022 8-K Quarterly results
11/08/2021 8-K Quarterly results
Docs: "Beam Therapeutics Provides Business and Pipeline Updates and Reports Third Quarter 2021 Financial Results BEAM-101 IND Cleared by FDA for Evaluation as a Treatment for Sickle Cell Disease BEAM-102 IND-Enabling Studies Also Underway CAMBRIDGE, Mass., Nov. 8, 2021 -Beam Therapeutics Inc."
08/10/2021 8-K Quarterly results
Docs: "Beam Therapeutics Provides Business and Pipeline Updates and Reports Second Quarter 2021 Financial Results Company On-track to Submit First IND for BEAM-101 in the Second Half of 2021 Continued Progress Across Base Editing Portfolio, Including Initiation of IND-Enabling Studies for BEAM-201 CAMBRIDGE, Mass., Aug. 10, 2021 -Beam Therapeutics Inc."
05/11/2021 8-K Quarterly results
11/10/2020 8-K Quarterly results
Docs: "Beam Therapeutics Announces Business and Pipeline Progress and Reports Third Quarter 2020 Financial Results BEAM-201, an Off the Shelf Allogeneic CD7-Targeting CAR-T, Named as Development Candidate for Treatment of T-ALL; First Cell Therapy Featuring Four Simultaneous Genetic Edits; Demonstrates 96-99% On-target Editing and In Vivo Proof of Concept of Tumor Clearance"
08/12/2020 8-K Quarterly results
03/30/2020 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : March 30, 2020 BEAM THERAPEUTICS INC. Delaware 001-39208 81-5238376 26 Landsdowne St. Cambridge, MA 02139 : 327-8775 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the...",
"Beam Therapeutics Reports Business Updates and Full Year 2019 Financial Results"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy